ReviewClinical pharmacokinetics2011
Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.
Review in Clinical pharmacokinetics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Variability of efavirenz plasma concentrations among pediatric HIV patients treated with efavirenz based combination antiretroviral therapy in Dar es Salaam, Tanzania.BMC pharmacology & toxicology · 2018Trial
- A randomized two-way crossover bioequivalence study in healthy adult volunteers of paediatric zidovudine/lamivudine/nevirapine fast-disintegrating fixed-dose combination tablet.The Journal of pharmacy and pharmacology · 2017Trial
- Is Routine Therapeutic Drug Monitoring of Anti-Retroviral Agents Warranted in Children Living with HIV?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2022Article
- Dosage Individualization of Linezolid: Precision Dosing of Linezolid To Optimize Efficacy and Minimize Toxicity.Antimicrobial agents and chemotherapy · 2021Article
- Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients.Pharmaceutics · 2019Article
- Individualization of piperacillin dosing for critically ill patients: dosing software to optimize antimicrobial therapy.Antimicrobial agents and chemotherapy · 2014Article
- Pharmacokinetic/pharmacodynamic modelling approaches in paediatric infectious diseases and immunology.Advanced drug delivery reviews · 2014Review
- Preventive misconception and adolescents' knowledge about HIV vaccine trials.Journal of medical ethics · 2013Article
- Software for dosage individualization of voriconazole for immunocompromised patients.Antimicrobial agents and chemotherapy · 2013Article
- Pharmacotherapy of pediatric HIV infection.Pediatric clinics of North America · 2012Review
- Pharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.Antimicrobial agents and chemotherapy · 2012Article
- High dose of darunavir in treatment-experienced HIV-infected adolescent results in virologic suppression and improved CD4 cell count.Therapeutic drug monitoring · 2012Article
- Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.British journal of clinical pharmacology · 2012Article
- Practical Considerations For Developing Nucleoside Reverse Transcriptase Inhibitors.Drug discovery today. Technologies · 2012Article
- Medical management of chronic liver diseases in children (part I): focus on curable or potentially curable diseases.Paediatric drugs · 2011Review
- Antiretroviral drugs in pediatric HIV-infected patients: pharmacokinetic and practical challenges.Paediatric drugs · 2011Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
There are over 2.1 million HIV-infected children worldwide, who are increasingly exposed to antiretroviral therapy. Given the enormous physiological changes associated with maturation, the role of individualized therapy and optimal dosing in children and adolescents is likely different than in adults. This review summarizes the pharmacodynamics, pharmacokinetics and pharmacogenomics of antiretroviral therapy in children and adolescents, and it discusses the roles of these in the optimization of therapy through the practice of therapeutic drug monitoring/management. Within the pharmacodynamics section are tables and discussion about what is known of the relationships between drug concentrations, inhibitory quotients and effects - both desired and toxic. The pharmacokinetics section summarizes all reported antiretroviral pharmacokinetic data in children, divided into data from population and non-population analytic approaches. Measures of interindividual pharmacokinetic variability are reported. Sampling strategies for the measurement and the interpretation of plasma antiretroviral drug concentrations are suggested, as well as dosing with degrees of renal or hepatic failure. Relevant pharmacogenomic polymorphisms are summarized, and the role for pharmacogenomics testing is discussed. Incorporation of dose adjustment on the basis of measured serum drug concentrations is reviewed, including all such paediatric experience reported in the literature. Discussion of the influences of malnutrition and herbal remedies is also included. Finally, consideration is given to future work in this field.
Indexed as
Identifiers
21294595What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.